. 2022 Aug 22;11(16):4929. doi: 10.3390/jcm11164929

Table 4.

Univariate and multivariate analyses for PTMC patients with bilateral disease.

	Univariate Analysis		Multivariate Analysis			Univariate Analysis		Multivariate Analysis
	Hazard Ratio (95% CI)	p Value	Hazard Ratio (95% CI)	p Value		Hazard Ratio (95% CI)	p Value	Hazard Ratio (95% CI)	p Value
*Factors selected*					*Factors selected*
Age		*0.007*		*0.004*	Age		0.716
≥55 vs. <55	*0.308 (0.131–0.724)*		*0.224 (0.080–0.626)*		≥55 vs. <55	1.312 (0.303–5.683)
BMI		0.609			BMI		0.255
>23 vs. ≤23	1.199 (0.599–2.401)				>23 vs. ≤23	1.952 (0.617–6.173)
Gender		0.072			Gender		0.025		0.293
Male vs. Female	2.034 (0.938–4.411)				Male vs. Female	*3.437 (1.168–10.118* )		2.052 (0.538–7.824)
TCI		*0.009*		*0.020*	TCI		0.739
Yes vs. No	*2.598 (1.263–5.344)*		*2.624 (1.161–5.929)*		Yes vs. No	0.838 (0.296–2.375)
Maximum tumor diameter		*0.038*		0.133	Maximum tumor diameter		0.850
>0.5 cm vs. ≤0.5 cm	*2.074 (1.040–4.137)*		1.836 (0.832–4.055)		>0.5 cm vs. ≤0.5 cm	1.109 (0.378–3.251)
Tumor location		0.143			Tumor location		0.438
Upper vs. Middle/Lower	0.583 (0.283–1.200)				Upper vs. Middle/Lower	0.612 (0.177–2.117)
Multifocality		*0.000*		*0.000*	Multifocality		0.071
Yes vs. No	*5.059 (2.417–10.590)*		*6.278 (2.728–14.451)*		Yes vs. No	3.451 (0.899–13.241)
PTMC with ipsilateral nodular goiter		0.966			PTMC with ipsilateral nodular goiter		*0.008*		*0.038*
Yes vs. No	0.984 (0.463–2.092)				Yes vs. No	*4.545 (1.489–13.876)*		*4.375 (1.083–17.670)*
PTMC with Hashimoto thyroiditis		0.468			PTMC with Hashimoto thyroiditis		0.635
Yes vs. No	1.327 (0.619–2.846)				Yes vs. No	0.754 (0.235–2.417)
					Maximum diameter of positive CLN		*0.000*		*0.000*
					>0.5 cm vs. ≤0.5 cm	*16.000 (4.052–63.185)*		*13.868 (3.226–59.610)*
					Number of positive CLN		0.090
					≥3 vs. <3	1.707 (0.919–3.170)